$854 Million is the total value of Logos Global Management LP's 40 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 280.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $69,808,500 | -21.4% | 1,350,000 | +3.8% | 8.18% | -25.1% |
| IMVT | New | IMMUNOVANT INC | $55,912,500 | – | 3,150,000 | +100.0% | 6.55% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $35,487,000 | +96.6% | 900,000 | +80.0% | 4.16% | +87.3% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $28,535,000 | +73.7% | 500,000 | +42.9% | 3.34% | +65.5% |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $17,415,000 | – | 60,000 | +100.0% | 2.04% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $14,677,500 | – | 750,000 | +100.0% | 1.72% | – |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $14,560,000 | -7.7% | 2,000,000 | +2.6% | 1.71% | -12.0% |
| New | ASTRIA THERAPEUTICS INC | $12,879,254 | – | 864,960 | +100.0% | 1.51% | – | |
| COGT | New | COGENT BIOSCIENCES INC | $12,716,000 | – | 1,100,000 | +100.0% | 1.49% | – |
| GERN | Buy | GERON CORP | $9,680,000 | +106.8% | 4,000,000 | +100.0% | 1.13% | +97.2% |
| FGEN | New | FIBROGEN INC | $8,410,500 | – | 525,000 | +100.0% | 0.98% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $8,200,400 | – | 260,000 | +100.0% | 0.96% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $7,837,500 | – | 1,250,000 | +100.0% | 0.92% | – |
| ANAB | New | ANAPTYSBIO INC | $7,747,500 | – | 250,000 | +100.0% | 0.91% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $6,838,200 | – | 180,000 | +100.0% | 0.80% | – |
| VERA | New | VERA THERAPEUTICS INCcl a | $5,514,750 | – | 285,000 | +100.0% | 0.65% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $5,500,000 | – | 50,000 | +100.0% | 0.64% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $3,960,000 | – | 200,000 | +100.0% | 0.46% | – |
| MOR | New | MORPHOSYS AGsponsored ads | $3,222,000 | – | 900,000 | +100.0% | 0.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.